Enovis (NYSE:ENOV) Posts Q1 Sales In Line With Estimates But Stock DropsMedical technology company Enovis Corporation (
NYSE:ENOV) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.3% year on year to $558.8 million. The company’s full-year revenue guidance of $2.24 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.81 per share was 8.9% above analysts’ consensus estimates.
Enovis (ENOV) Q1 Earnings Report Preview: What To Look ForMedical technology company Enovis Corporation (
NYSE:ENOV) will be reporting results tomorrow before market hours. Here’s what to look for.
3 Dawdling Stocks in Hot WaterLow-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
1 Unprofitable Stock with Competitive Advantages and 2 to QuestionUnprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Reasons to Sell ENOV and 1 Stock to Buy InsteadWhat a brutal six months it’s been for Enovis. The stock has dropped 22.5% and now trades at $31.96, rattling many shareholders. This might have investors contemplating their next move.
Enovis to Host First Quarter 2025 Results Conference Call on May 8thWilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (
NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com.
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Think Twice AboutWall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Spotting Winners: STAAR Surgical (NASDAQ:STAA) And Medical Devices & Supplies - Specialty Stocks In Q4Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including STAAR Surgical (
NASDAQ:STAA) and its peers.
Medical Devices & Supplies - Specialty Stocks Q4 Teardown: Integer Holdings (NYSE:ITGR) Vs The RestLet’s dig into the relative performance of Integer Holdings (
NYSE:ITGR) and its peers as we unravel the now-completed Q4 medical devices & supplies - specialty earnings season.
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty SegmentLooking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (
NYSE:BLCO) and its peers.
Enovis Announces Appointment of Damien McDonald as Chief Executive OfficerWIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (
NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million.
2 Healthcare Stocks with Solid Fundamentals and 1 to Turn DownHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 11.1%. This drop was worse than the S&P 500’s 4% loss.
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025Alongside an evidence-based portfolio, Enovis will showcase how it’s “Redefining Every Step” with confidence-building education and a partnership that goes beyond the product; attendees invited to exclusive events.
3 Stocks Under $50 in the DoghouseStocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs PeersLooking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (
NYSE:GMED) and its peers.
Enovis to Participate in Upcoming Investor ConferencesWilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (
NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The PackQuarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (
NASDAQ:STAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Enovis (NYSE:ENOV) Exceeds Q4 ExpectationsMedical technology company Enovis Corporation (
NYSE:ENOV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 23.3% year on year to $561 million. On the other hand, the company’s full-year revenue guidance of $2.21 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $0.98 per share was 7% above analysts’ consensus estimates.
Enovis Announces Fourth Quarter and Full Year 2024 ResultsWilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (
NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Enovis Announces Planned CEO Succession ProcessWilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (
NYSE: ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the “Board”) of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO. As part of the Company’s succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to serve as the Company’s next CEO.
Enovis (ENOV) Q4 Earnings: What To ExpectMedical technology company Enovis Corporation (
NYSE:ENOV) will be announcing earnings results tomorrow before market open. Here’s what to expect.
